Role of rat liver cytochrome P450 3A and 2D in metabolism of imrecoxib

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Acta Pharmacologica Sinica

• Publication date

  2006-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/j.1745-7254.2006.00265.xPMID 16490176
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increased risk of cardiovascular events with coxibs and NSAIDs.

  2005cited by this paper
• Increased risk of cardiovascular events with coxibs and NSAIDs.

  2005cited by this paper
• Adverse cardiovascular effects of the coxibs.

  2005cited by this paper
• Characterization of enzymes responsible for biotransformation of the new antileukotrienic drug quinlukast in rat liver microsomes and in primary cultures of rat hepatocytes

  2004cited by this paper
• Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect.

  2004cited by this paper
• COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.

  2004cited by this paper
• Cytochrome P450 isoenzymes involved in rat liver microsomal metabolism of californine and protopine.

  2004cited by this paper
• The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.

  2003cited by this paper
• 4'-hydroxylation of flurbiprofen by rat liver microsomes in fasting and feeding conditions.

  2003cited by this paper
• Metabolism of roxithromycin in phenobarbital-treated rat liver microsomes.

  2002cited by this paper
• Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase.

  2002cited by this paper
• Inhibitory effect of 3,4-diaryl-3-pyrrolin-2-one derivatives on cyclooxygenase 1 and 2 in murine peritoneal macrophages.

  2002cited by this paper
• Effect of phenobarbital and spironolactone treatment on the oxidative metabolism of antipyrine by rat liver microsomes.

  2001cited by this paper
• Rat cytochrome p450 1A and 3A enzymes involved in bioactivation of tegafur to 5-fluorouracil and autoinduced by tegafur in liver microsomes.

  2001cited by this paper
• Design, Synthesis and in vitro Evaluation of a New Class of Novel Cyclooxygenase-2 Inhibitors: 3, 4-diaryl-3-pyrrolin-2-ones

  2001cited by this paper
• Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.

  1998cited by this paper
• Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system.

  1997cited by this paper
• Pain management in osteoarthritis: the role of COX-2 inhibitors.

  1997cited by this paper
• Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.

  1997cited by this paper
• Review article: COX‐II inhibitors—a new generation of safer NSAIDs?

  1997cited by this paper
• The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome.

  1997cited by this paper
• The discovery and function of COX-2.

  1997cited by this paper
• Cyclo-oxygenase isoenzymes. How recent findings affect thinking about nonsteroidal anti-inflammatory drugs.

  1997cited by this paper
• Prostaglandin endoperoxide H synthases-1 and -2.

  1996cited by this paper
• Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

  1994cited by this paper
• Species variation in the response of the cytochrome P-450-dependent monooxygenase system to inducers and inhibitors.

  1990cited by this paper
• A pharmacokinetic analysis program (multi) for microcomputer.

  1981cited by this paper
• Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.

  1971cited by this paper
• Aspirin selectively inhibits prostaglandin production in human platelets.

  1971cited by this paper
• THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

  1964cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects: A Comparative Study

  2025cites this paper
• Comparative Pharmacokinetics and Safety of Imrecoxib, a Novel Selective Cyclooxygenase-2 Inhibitor, in Elderly Healthy Subjects

  2022cites this paper
• Inhibition of imrecoxib on mRNA and protein expression of CYP2C11 enzyme in rats.

  2022cites this paper
• Dose Investigation of Imrecoxib in Patients with Renal Insufficiency Based on Modelling and Simulation.

  2020cites this paper
• Biotransformation and bioactivation reactions – 2018 literature highlights

  2019cites this paper
• Effect of Fluconazole on the Pharmacokinetic Properties of Imrecoxib, a Novel NSAID: A Single-center, Open-label, Self-controlled Study in Healthy Chinese Male Volunteers.

  2018cites this paper
• Differences in the In Vivo and In Vitro Metabolism of Imrecoxib in Humans: Formation of the Rate-Limiting Aldehyde Intermediate

  2018cites this paper
• A Systematic Review and Meta-Analysis of the Efficacy of Piracetam and Piracetam-Like Compounds in Experimental Stroke

  2007cites this paper
• Formation of 4′-carboxyl acid metabolite of imrecoxib by rat liver microsomes

  2006cites this paper